DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Over 1500 stakeholders representing food businesses, packaging industries, recycling associations, regulatory bodies, environmental organizations, consumer groups, farmer groups, government departments participated in the consultation
SmartTrack aims to reduce the need for clinical studies in generic drug product approvals
Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Women Health Card was launched exclusively for women health workers of the Tiruchirappalli City Corporation
This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States
This partnership encompasses dossier licensing, bulk product supply, and the licensing of ZIM Labs’ proprietary Oral Thin Film technology platform, ThinOral
This study enrolled a total of 204 healthy volunteers into three groups to compare BP16 with the reference products, Prolia, obtained from both the EU and US markets
Subscribe To Our Newsletter & Stay Updated
